These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 23093698)

  • 1. Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy.
    Hajje G; Borget I; Leboulleux S; Chougnet C; Al Ghuzlan A; Mirghani H; Caramella C; Hartl D; Schlumberger M; Baudin E
    Eur J Endocrinol; 2013 Feb; 168(2):113-8. PubMed ID: 23093698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times.
    Laure Giraudet A; Al Ghulzan A; Aupérin A; Leboulleux S; Chehboun A; Troalen F; Dromain C; Lumbroso J; Baudin E; Schlumberger M
    Eur J Endocrinol; 2008 Feb; 158(2):239-46. PubMed ID: 18230832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma.
    Barbet J; Campion L; Kraeber-Bodéré F; Chatal JF;
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6077-84. PubMed ID: 16091497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Usefulness of serum calcitonin, CEA and AFP assays in the early detection of medullary thyroid carcinoma relapse].
    Łacka K; Michałek K; Majewski P
    Wiad Lek; 2002; 55(7-8):394-403. PubMed ID: 12428567
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Souteiro P; Gouveia P; Ferreira G; Belo S; Costa C; Carvalho D; Duarte H; Sampaio IL
    Endocrine; 2019 May; 64(2):322-329. PubMed ID: 30684230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of elevated serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma.
    Bockhorn M; Frilling A; Rewerk S; Liedke M; Dirsch O; Schmid KW; Broelsch CE
    Thyroid; 2004 Jun; 14(6):468-70. PubMed ID: 15242577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
    Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
    Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer.
    Elisei R; Lorusso L; Piaggi P; Torregrossa L; Pellegrini G; Molinaro E; Agate L; Bottici V; Pani F; Cacciato Insilla A; Casella F; Ciampi R; Tognetti I; Materazzi G; Basolo F; Romei C
    Eur J Endocrinol; 2015 Sep; 173(3):297-304. PubMed ID: 26034076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating calcitonin and carcinoembryonic antigen m-RNA detected by RT-PCR as tumour markers in medullary thyroid carcinoma.
    Bojunga J; Dragan C; Schumm-Draeger PM; Usadel KH; Kusterer K
    Br J Cancer; 2001 Nov; 85(10):1546-50. PubMed ID: 11720443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medullary thyroid carcinoma surgical cytoreduction induces an increase in serum calcitonin and carcinoembryonic antigen doubling times.
    Papapetrou PD; Polymeris A
    Exp Clin Endocrinol Diabetes; 2012 Mar; 120(3):164-8. PubMed ID: 22328112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic variables and calcitonin in medullary thyroid cancer.
    Clark JR; Fridman TR; Odell MJ; Brierley J; Walfish PG; Freeman JL
    Laryngoscope; 2005 Aug; 115(8):1445-50. PubMed ID: 16094121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in risk factors and Tumor Node Metastasis stage of sporadic medullary thyroid carcinoma over 41 years, before and after the routine measurements of serum calcitonin.
    Karga H; Giagourta I; Papaioannou G; Doumouchtsis K; Polymeris A; Thanou S; Papamichael K; Zerva C
    Metabolism; 2011 May; 60(5):604-8. PubMed ID: 20667564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic values of the doubling time of serum carcinoembryonic antigen and calcitonin levels in medullary thyroid carcinoma].
    Miyauchi A; Onishi T; Matsuzuka F; Hirai K; Kuma K; Takai S; Nakamoto K; Nakamura K; Nanjo S; Maeda M
    Gan No Rinsho; 1986 Oct; 32(12):1519-24. PubMed ID: 3783976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.
    Lupone G; Antonino A; Rosato A; Zenone P; Iervolino EM; Grillo M; De Palma M
    G Chir; 2012; 33(11-12):395-9. PubMed ID: 23140924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen.
    Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M
    Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum calcitonin-negative medullary thyroid carcinoma: role of CgA and CEA as complementary markers.
    Giovanella L; Crippa S; Cariani L
    Int J Biol Markers; 2008; 23(2):129-31. PubMed ID: 18629788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment.
    Werner RA; Schmid JS; Muegge DO; Lückerath K; Higuchi T; Hänscheid H; Grelle I; Reiners C; Herrmann K; Buck AK; Lapa C
    Medicine (Baltimore); 2015 Nov; 94(45):e2016. PubMed ID: 26559299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M
    J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
    Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
    Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Follow-up in Medullary Thyroid Carcinoma.
    Raue F; Frank-Raue K
    Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.